Across countries and income levels, many women reach midlife without a clear understanding of menopause — and that gap can carry real health consequences. In 2019, 38-year-old Rosy Devi of Bihar, India, entered menopause after a hysterectomy and since then has faced persistent body aches, breathlessness and chest pain that she links to the abrupt hormonal change. Experts warn that these experiences are not isolated: menopause affects roughly half the global population at some point, and insufficient public and clinical knowledge can delay diagnosis, limit treatment options and raise long-term risks. This report outlines what menopause is, how awareness varies worldwide, and why that matters for individual and public health.
Key takeaways
- Menopause marks 12 consecutive months without menstruation and typically occurs between ages 45 and 55, per WHO guidance.
- Studies report up to 9.4% of people experience menopause at 40–44 and about 8.6% before age 40, meaning an important minority faces early or premature onset.
- Common symptoms — hot flashes and night sweats — affect around 80% of women, but many also report fatigue, joint pain, palpitations, sleep disruption and mood changes.
- Menopause raises long-term risks, including higher rates of cardiovascular disease and some respiratory conditions, especially after premature menopause.
- Hormone therapy (HRT) is the most prescribed treatment and can reduce symptoms and some risks, but access, cost and clinician familiarity vary widely between and within countries.
- Low awareness among the public and some health professionals leaves many women feeling dismissed, under-treated or unaware that lifestyle changes and treatments can help.
- In settings such as parts of India, higher rates of hysterectomy and limited informed consent create greater burdens of early menopause among disadvantaged women.
Background
Menopause is the permanent end of menstruation, defined clinically after 12 months without a period; the transition commonly begins with perimenopause when ovarian hormone production declines and cycles become irregular. The World Health Organization places the most common age range for natural menopause between 45 and 55, but research in countries including the United States and South Korea documents meaningful proportions of earlier onset: roughly 9.4% at ages 40–44 and about 8.6% before 40. Perimenopause can start years earlier — sometimes in the mid-30s — and its gradual onset means many women do not identify the change at first.
Large surveys of postmenopausal women show substantial gaps in education: in one study of more than 800 respondents (mostly in the UK), over 90% said menopause was not taught in school and nearly half felt uninformed. Those same respondents often reported that clinicians lacked sufficient training to address their concerns, leaving patients feeling dismissed. Researchers and clinicians say this combination — low public awareness and uneven professional knowledge — contributes to delayed diagnosis, inadequate symptom management and missed opportunities to reduce long-term health risks.
Main event
Symptoms commonly associated with menopause — hot flashes and night sweats — are well known, but the symptom profile is far broader. Many women experience sleep disturbance, mood shifts, vaginal dryness, urinary urgency, reduced libido, joint and muscle pain, headaches and cognitive difficulties such as poor concentration. Less common complaints include changes in vision, dry mouth, bruising and scalp or skin itchiness; these varied presentations can complicate clinical recognition.
Menopause can occur naturally, be triggered surgically by hysterectomy with oophorectomy, or result from medical treatments such as chemotherapy and pelvic radiation. Surgical and medically induced menopause tend to produce abrupt hormone loss and more intense short-term symptoms compared with the gradual decline seen in natural perimenopause. In many low- and middle-income settings, studies report elevated rates of hysterectomy among younger women, which is linked to higher rates of premature menopause.
In parts of India, research and clinician reports point to a pattern in which women from lower-income, rural and less-educated backgrounds undergo hysterectomies for conditions like heavy bleeding or fibroids without full awareness of the procedure’s reproductive consequences. Experts say social pressures and clinician practice patterns may influence treatment decisions, increasing the burden of early menopause among already vulnerable groups. Individual stories like Rosy Devi’s — sudden post-surgical onset of severe symptoms and persistent decline in wellbeing — illustrate how lack of informed consent and limited follow-up care can exacerbate harms.
Analysis & implications
Declining estrogen at menopause has measurable effects on cardiovascular risk factors: estrogen helps regulate cholesterol and fat distribution, and its loss is associated with higher LDL cholesterol and central weight gain. Public-health bodies warn that the postmenopausal period is a time of heightened risk for coronary heart disease, stroke and other vascular events, making prevention and monitoring important for long-term outcomes. Because heart disease remains the leading cause of death among women globally, gaps in menopause care represent a missed preventive opportunity.
Premature and early menopause extend the duration of risk exposure: women who lose ovarian function decades earlier face a longer window of increased cardiovascular and bone health vulnerability. Studies also link menopause to higher rates of some respiratory conditions — including a greater risk of COPD — and growing evidence points to elevated rates of depression and anxiety around the menopausal transition. These multi-system effects argue for integrated care that addresses cardiovascular, respiratory, bone and mental health rather than treating vasomotor symptoms alone.
Access to effective treatments such as hormone replacement therapy is uneven. HRT can relieve symptoms and in some cases reduce long-term risks, but it carries side effects and small absolute increases in certain cancer and clotting risks depending on type, dose and duration. Cost, clinician familiarity, cultural attitudes and regulatory messaging all shape uptake; changes in regulatory labels — including recent decisions in some jurisdictions to revise warnings on HRT products — may shift clinician and patient behavior, but the scale of any change is uncertain without monitoring.
Comparison & data
| Measure | Statistic |
|---|---|
| Typical age of natural menopause (WHO) | 45–55 years |
| Menopause at 40–44 (study) | up to 9.4% |
| Menopause before 40 (premature) | about 8.6% |
| Hot flashes/night sweats prevalence | ~80% |
| Average symptom duration (Cleveland Clinic) | around 7 years |
This table aggregates major figures cited in international guidance and peer-reviewed studies to provide a quick baseline for policymakers and clinicians. The numbers show that while most women experience menopause in midlife, nontrivial percentages face earlier transitions — a finding with implications for screening, workplace policies and long-term care planning. Symptom prevalence and duration underline the need for sustained clinical support rather than short-term interventions alone.
Reactions & quotes
Clinicians and researchers emphasize the education gap and its consequences for patient care. The following excerpts reflect expert concerns and calls to action.
“Women have a lack of education about this key life stage…Together with a reported lack of education from their healthcare professionals, women may be left undiagnosed and unsupported.”
Joyce Harper, Professor, UCL Institute of Women’s Health
Advocates in public health stress the need for policy change to address post-reproductive health needs as populations age.
“The government often focuses on reproductive health, not post-reproductive care; we need policies that recognise women beyond their childbearing years.”
Nikita Rajput, Scientific Officer, Tata Memorial Centre
Researchers point to the practical benefits of awareness and lifestyle measures as complements to medical treatment.
“Once you understand your symptoms … these can be managed well through lifestyle, screening and targeted therapy.”
Om Kurmi, Associate Professor, Coventry University
Unconfirmed
- Extent to which recent regulatory label changes will increase HRT uptake globally remains unclear and unmeasured in many countries.
- Causal links between rising hysterectomy rates and national changes in premature menopause require further longitudinal research to establish directionality and underlying drivers.
- Reports that women were compelled into hysterectomy by family members or clinicians exist in qualitative studies, but the prevalence and legal or systemic mechanisms vary by region and need broader quantitative confirmation.
Bottom line
Menopause is a near-universal biological transition with a wide spectrum of symptoms and measurable long-term health implications, yet public understanding and clinical preparedness are uneven worldwide. The combination of early/premature onset in a meaningful minority, inadequate patient education, and variable access to effective therapies creates preventable health burdens — from untreated vasomotor symptoms to higher cardiovascular and respiratory risk over decades.
Addressing the problem requires a multipronged approach: integrate menopause into health education (including school curricula), improve clinician training and guidelines, expand access to evidence-based treatments where appropriate, and design social policies that recognise post-reproductive health needs. Better data collection and monitoring of outcomes after policy or label changes will be essential to measure progress and guide interventions.
Sources
- CNN (news report) — original reporting and interviews
- World Health Organization (official) — guidance on typical age ranges and definitions
- The North American Menopause Society (clinical guidance) — symptom prevalence and treatment overview
- Cleveland Clinic (clinical information) — average symptom duration
- British Heart Foundation (health charity) — information on cardiovascular risk after menopause
- Mayo Clinic (clinical reference) — list of symptoms and management options
- U.S. Food and Drug Administration (official) — regulatory actions and guidance on hormone therapy